rs2235015

A SNP in the ABCB1 gene on chromosome 7. Its most notable genotype is C;C: common/normal

Gene
ABCB1
Location
Chr 787,570,248 (GRCh38)
Highest magnitude
0.0Typical
Tested on
23andMe, AncestryDNA, FamilyTreeDNA
Minor allele frequency
20%

Genotypes

Plus strand, as in 23andMe and AncestryDNA files.

  1. C;CMost notableGoodcommon/normalTypical · 0.062% of people

SNPedia records rs2235015 on the minus strand: (G;G). Magnitude rates how notable a genotype is from 0 to 10, not how risky it is.

Frequency

Share of each genotype in 11 HapMap populations.

  • AverageC;C 62%
  • European ancestry (Utah)C;C 56%
  • Han Chinese (Beijing)C;C 91%
  • Japanese (Tokyo)C;C 82%
  • Yoruba (Nigeria)C;C 28%
  • African ancestry (Southwest US)C;C 51%
  • Chinese (Denver)C;C 93%
  • Gujarati IndianC;C 65%
  • Luhya (Kenya)C;C 36%
  • Mexican ancestry (Los Angeles)C;C 71%
  • Maasai (Kenya)C;C 44%
  • TuscanC;C 65%

Notes

From SNPedia

Show notes, about 370 words

rs2235015 is a SNP in the ABCB1 gene (also known as the MDR1 gene), which encodes a protein (P-glycoprotein - Pgp) that transports certain molecules across the blood-brain barrier. SNPs in ABCB1 may thus influence the intracerebral concentrations of certain drugs and their efficacy or potential for adverse side effects. Clinical studies on antidepressant drug dosage, plasma medication levels and treatment outcome suggest monotonic associations for tricyclic antidepressant drugs and threshold models or higher order relationships for selective serotonin reuptake inhibitors PMID 28648553 and newer antidepressant drugs ,. However, the link between the increased brain concentrations of antidepressants and a clinically significant response is still to be confirmed. According to a recent review , ten studies reported that ABCB1 SNPs have clinical effect on depression outcome and eight - that they do not. However those 18 studies are difficult to compare because they vary within their study design concerning following factors: population (ethnicity, psychiatric condition), tested SNPs, tested antidepressants (Pgp substrates and Pgp non-substrates) and doses, inclusion of drug metabolism monitoring and statistical correction for multiple testing. A study of ~400 of German psychiatric inpatients with depression conducted in 2007 by Uhr et al found that rs2235015(T) carriers treated with ABCB1 substrates were more likely to remit. However, this result could not be reproduced in a large (N~900) trial with outpatients with major depression treated with the ABCB1 substrate citalopram (STAR-D study, level 1). According to a recent meta analysis , no significant association of antidepressant treatment outcome with this SNP among all studies, but the association remained significant in a subgroup-analysis of all inpatients. rs2235015 is near the 9 SNPs found within a tight linkage block (r 2 >= 0.8 ) such that the minor allele at any one of them predicts (with ~80%+ accuracy) that the other SNPs will also be the minor allele. The list of the 9 SNPs is shown below. rs2235015 has an r 2 value of >0.5 with this group : * rs2235067 * rs4148740 * rs2032583 * rs4148739 * rs11983225 * rs2235040 * rs12720067 * rs7787082 * rs10248420

Source and license

Adapted from rs2235015 on SNPedia, using a snapshot taken October 16, 2026. SNPedia content is shared under CC BY-NC-SA 3.0 US, and this page is shared under the same license.

SNPedia is a community-edited wiki. Its entries can be incomplete, out of date or wrong, and nothing here is a diagnosis or medical advice. Magnitude is a community rating of how interesting a genotype is, not a risk score.